Indication
Co-administered with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

Medicine details

Medicine name:
rivaroxaban (Xarelto)
SMC ID:
SMC2128
Pharmaceutical company
Bayer Plc
BNF chapter
Cardiovascular system
Submission type
Full submission
Status
Advice due date:
11 February 2019
SMC meeting date:
08 January 2019
Patient group submission deadline:
03 December 2018